John Rother President, National Coalition on Health Care Introduction The price of pharmaceuticals has been a top policy issue in the U.S., especially since the introduction of the $1000 per pill Hep C drug Sovaldi in 2017. Drug prices are a top concern for Americans going into the fall elections. The issue is driven by […]
On Monday, June 29, Gilead announced the pricing of remdesivir, an anti-viral drug that treats COVID-19. The Coalition supports protecting consumers from unaffordable drug costs. The pricing decision will exacerbate the health care affordability crisis already plaguing the country’s response to COVID-19. Fundamentally, the United States needs to develop a fair drug pricing system that […]
On Monday, June 29, the House passed the Patient Protection and Affordable Care Enhancement Act (H.R. 1425). The Coalition supports protecting consumers from unaffordable health care costs in the individual market and creating overdue incentives for more states to expand Medicaid coverage. Read the Coalition’s statement on the bill here.
House Democrats unveiled H.R. 1425 which would expand and protect key elements of the Affordable Care Act (ACA). Key provisions of H.R. 1425 include expanding subsidies and eligibility requirements for state-level exchanges. Importantly, states would have the ability to expand premium tax credits beyond 400% of the federal poverty line. H.R. 1425 also fixes the […]
On June 17, NCHC published a one-pager discussing COVID-19’s impact on primary care. Recent policy solutions have not offered direct financial assistance to independent primary care practices. Without financial assistance, some independent primary care practices may close indefinitely, which will harm chronic disease management, COVID-19 diagnoses, and much more. This one-pager offers policy solutions to […]